

# Clinical trials of ticlopidine

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 acute myocardial infarction

| Trial  | Treatments                               | Patients          | Trials design and methods       |
|--|--|-------------------|---------------------------------|
| <b>ticlopidine vs control</b>                                |  |                   |                                 |
| <a href="#">Knudsen-A , 1985</a><br>n=24/19<br>follow-up: 3m | ticlopidine 500mg/d<br>versus<br>placebo | patients with AMI | Parallel groups<br>double blind |

More details and results :

- antiplatelets drug for acute myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q390>

## References

### Knudsen-A, 1985:

Knudsen JB, Kjeller E, Skagen K, Gormsen J The effect of ticlopidine on platelet functions in acute myocardial infarction. A double blind controlled trial. Thromb Haemost 1985;53:332-6 [[3901391](#)]

## 2 cardiovascular prevention

| Trial  | Treatments   | Patients  | Trials design and methods       |
|--|--|---|---------------------------------|
| <b>ticlopidine vs placebo</b>                                    |  |   |                                 |
| <a href="#">Ellis , 1986</a><br>n=100/103<br>follow-up: 6 months | Ticlopidine 500 mg/j<br>versus<br>Placebo                                | AOMI stade II   | Parallel groups<br>double blind |
| <a href="#">Hurlow , 1980</a><br>n=30/30<br>follow-up:           | Ticlopidine : 100 -500 mg / jour pendant<br>2 mois.<br>versus<br>Placebo | Donnes non disponibles  | Parallel groups<br>double blind |
| <a href="#">Berglund , 1985</a><br>n=21/17<br>follow-up: 2m      | ticlopidine 500 mg daily<br>versus<br>placebo                            | middle-aged men with stable<br>incapacitating angina pectoris | parallel groups<br>double blind |

continued...

| <b>Trial</b>   | <b>Treatments</b>  | <b>Patients</b>   | <b>Trials design and methods</b> |
|--|--|---|----------------------------------|
| <b>Krause , 1980</b><br>n=19/19<br>follow-up:  | Ticlopidine : 500 mg pendant 4 mois<br>versus<br>Placebo | Donnes non disponibles  | Parallel groups<br>double blind  |
| <b>Katsumara , 1982</b><br>n=93/100<br>follow-up: 6 semaines                           | Ticlopidine 500 mg/j<br>versus<br>Placebo                | patients with ischemic ulcers due to<br>chronic arterial occlusion  | Parallel groups<br>double blind  |
| <b>Birmingham-A , 1979</b><br><i>unpublished</i><br>n=20/8<br>follow-up: 2 months      | -  | -   | Parallel groups                  |
| <b>Aukland , 1982</b><br>n=33/32<br>follow-up: 1 y                                     | Ticlopidine 500 mg/j<br>versus<br>Placebo                | men with atherosclerotic intermittent<br>claudication and haemorheological<br>abnormalities                     | Parallel groups<br>double blind  |
| <b>London diabetes , 1983</b><br><i>unpublished</i><br>n=38/40<br>follow-up: 12 months | -  | -   | Parallel groups                  |
| <b>Stiegler , 1984</b><br>n=57/57<br>follow-up:  | Ticlopidine 500 mg/j<br>versus<br>Placebo                | AOMI stade II   | Parallel groups<br>double blind  |
| <b>TIMAD , 1984</b><br>n=220/215<br>follow-up: 32m                                     | -  | -   | Parallel groups                  |
| <b>BTRS , 1992</b><br>n=49/51<br>follow-up: 48 months                                  | ticlopidine 500mg/d<br>versus<br>placebo                 | insulin-treated diabetics with background<br>retinopathy  | Parallel groups<br>double blind  |
| <b>Nyberg , 1984</b><br>n=12/11<br>follow-up: 12 months                                | ticlopidine 500mg daily<br>versus<br>placebo             | insulin dependent diabetes complicated<br>by nephropathy  | Parallel groups<br>double blind  |
| <b>Cloarec , 1986</b><br>n=66/66<br>follow-up: 1 y                                     | Ticlopidine 500 mg/j<br>versus<br>Placebo                | AOMI stade non precis   | Parallel groups<br>double blind  |
| <b>Arcan , 1988</b><br>n=83/86<br>follow-up: 6 months                                  | Ticlopidine 500 mg/j<br>versus<br>Placebo                | patients with chronic intermittent<br>claudication due to obstructive peripheral<br>vascular disease (stade II) | Parallel groups<br>double blind  |
| <b>Balsano , 1989</b><br>n=76/75<br>follow-up: 21 months                               | Ticlopidine 500 mg/j<br>versus<br>Placebo                | patients with intermittent claudication<br>(stade II)   | Parallel groups<br>double blind  |

continued...

| Trial   | Treatments                                | Patients  | Trials design and methods       |
|---|---|---|---------------------------------|
| STIMS , 1990<br>n=346/341<br>follow-up: 5.6 y | Ticlopidine 500 mg/j<br>versus<br>Placebo | patients with intermittent claudication<br>(stade II) | Parallel groups<br>double blind |
| EMATAP , 1993<br>n=304/311<br>follow-up:      | Ticlopidine 500 mg/j<br>versus<br>Placebo | AOMI stade non precis                                 | Parallel groups<br>double blind |

More details and results :

- antiplatelets drug for cardiovascular prevention in diabetic patients at <http://www.trialresultscenter.org/go-Q220>
- antiplatelets drug for cardiovascular prevention in secondary prevention in patients with intermittent claudication at <http://www.trialresultscenter.org/go-Q275>
- antiplatelets drug for cardiovascular prevention in secondary prevention in patients with CAD at <http://www.trialresultscenter.org/go-Q276>

## References

### Ellis, 1986:

DJ Ellis, BR Kamm. Treatment of intermittent claudication with Ticlopidine. Institute of Clinical Medicine, Syntex Research. Palo Alto, CA 94304, USA. Modifier — Effacer — pdf

### Hurlow, 1980:

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration BMJ 2002 Jan 12;324:71-86 [[11786451](#)]

### Berglund, 1985:

Berglund U, von Schenck H, Wallentin L Effects of ticlopidine of platelet function in men with stable angina pectoris. Thromb Haemost 1985;54:808-12 [[3911481](#)]

### Krause, 1980:

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration BMJ 2002 Jan 12;324:71-86 [[11786451](#)]

### Katsumara, 1982:

Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases, a double-blind study versus placebo. Katsumura T, Mishima Y, Kamiya K, Sakaguchi S, Tanabe T, Sakuma A Angiology 1982 Jun;33:357-67 [[7046521](#)]

### Birmingham-A, 1979:

unpublished

Pollock A, Wright AD Guildford: Sanofi Winthrop, 1979:(Sanofi internal report 105602-0010)

### Auckland, 1982:

Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication. Aukland A, Hurlow RA, George AJ, Stuart J J Clin Pathol 1982 Jul;35:740-3 [7047575]

**London diabetes, 1983:**

unpublished

Oakley NW, Dormandy JA, Flute PT. Guildford: Sanofi Winthrop, 1983:(Internal report 105602-0019.)

**Stiegler, 1984:**

H Stiegler, H Hess, A Mietaschk, H-J, Trampisch and Ingrisich. DMW 1984, 109:1240-1243.

**TIMAD, 1984:**

Mirouze J Agents Actions 1984;15(suppl):230-58

**BTRS, 1992:**

Ophthalmologica 1992;204:4-12 [1579337]

**Nyberg, 1984:**

Nyberg G, Larsson O, Westberg NG, Aurell M, Jagenburg R, Blohm G Clin Nephrol 1984;21:184-7 [6705280]

**Cloarec, 1986:**

Cloarec M et al Double-blind clinical trial of ticlopidine versus placebo in peripheral atherosclerotic disease of the legs Thrombosis Research 1986 suppl VI abstr 316

**Arcan, 1988:**

Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Arcan JC, Blanchard J, Boissel JP, Destors JM, Panak E Angiology 1988 Sep;39:802-11 [3048155]

**Balsano, 1989:**

Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. Balsano F, Coccheri S, Libretti A, Nenci GG, Catalano M, Fortunato G, Grasselli S, Violi F, Hellemans H, Vanhove P J Lab Clin Med 1989 Jul;114:84-91 [2661700]

**STIMS, 1990:**

Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. Janzon L, Bergqvist D, Boberg J, Boberg M, Eriksson I, Lindgarde F, Persson G, Almgren B, Fagher B, Kjellstrom T, et al J Intern Med 1990 May;227:301-8 [2187948]

**EMATAP, 1993:**

J Blanchard, LO Carrerars, M Kindermans and the EMATAP group. Results of EMATAP: a dooble-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease. Nouv Rev fr Hematol( 1993)35:523-528.

### 3 stable angina

| Trial                  | Treatments | Patients | Trials design and methods |
|------------------------|------------|----------|---------------------------|
| ticlopidine vs placebo |            |          |                           |

continued...

| Trial   | Treatments                                    | Patients  | Trials design and methods       |
|---|---|---|---------------------------------|
| <a href="#">Berglund , 1985</a><br>n=21/17<br>follow-up: 2m | ticlopidine 500 mg daily<br>versus<br>placebo | middle-aged men with stable<br>incapacitating angina pectoris | parallel groups<br>double blind |

More details and results :

- antithrombotics for stable angina in all type of patient at <http://www.trialresultscenter.org/go-Q33>

## References

### Berglund, 1985:

Berglund U, von Schenck H, Wallentin L Effects of ticlopidine of platelet function in men with stable angina pectoris. Thromb Haemost 1985;54:808-12 [[3911481](#)]

## 4 acute coronary syndrome

| Trial   | Treatments  | Patients   | Trials design and methods       |
|---|---|--|---------------------------------|
| <b>ticlopidine vs control</b>                                       |   |  |                                 |
| <a href="#">STAI , 1990</a><br>n=314/338<br>follow-up: 6m           | ticlopidine 250 mg b.i.d<br>versus<br>untreated control | patients with unstable angina <=48hrs<br>from the pain onset | single blind                    |
| <a href="#">Knudsen-A , 1985</a><br>n=24/19<br>follow-up: 3m        | ticlopidine 500mg/d<br>versus<br>placebo                | patients with AMI  | Parallel groups<br>double blind |
| <b>ticlopidine vs placebo</b>                                       |   |  |                                 |
| <a href="#">Florida UA unpublished</a><br>n=12/12<br>follow-up: 14d | -   | -  |                                 |

More details and results :

- antithrombotics for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q24>
- antiplatelets drug for acute coronary syndrome in ACS (excluding AMI) at <http://www.trialresultscenter.org/go-Q169>
- antiplatelets drug for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q346>
- antiplatelets drug for acute coronary syndrome in STEMI patients at <http://www.trialresultscenter.org/go-Q564>

## References

### STAI, 1990:

Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, Pasotti C, Rudelli G Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation 1990;82:17-26 [2194694]

Scrutinio D, Lagioia R, Rizzon P Ticlopidine treatment for patients with unstable angina at rest. A further analysis of the study of ticlopidine in unstable angina. Studio della Ticlopidina nell'Angina Instabile Group. Eur Heart J 1991;12 Suppl G:27-9 [1806376]

### Knudsen-A, 1985:

Knudsen JB, Kjeller E, Skagen K, Gormsen J The effect of ticlopidine on platelet functions in acute myocardial infarction. A double blind controlled trial. Thromb Haemost 1985;53:332-6 [3901391]

### Florida UA, 0:

unpublished

Mehta JL Unit de Pharmacologie Clinique, 1987. (Unit de Pharmacologie Clinique unpublished report)

## 5 thrombosis prevention

| Trial  | Treatments                       | Patients                              | Trials design and methods       |
|--|----------------------------------|---------------------------------------|---------------------------------|
| <b>Ticlopidine vs placebo</b>                                    |                                  |                                       |                                 |
| Lasierra , 1982<br>n=40/40                                       | Ticlopidine<br>versus<br>placebo | -                                     | double-blind                    |
| Walker , 1974 <i>unpublished</i><br>n=31/33                      | ticlopidine<br>versus<br>placebo | -                                     | double-blind                    |
| McKenna-II , 1983<br>n=29/29<br>follow-up: 2 weeks               | Ticlopidine<br>versus<br>placebo | Elective orthopaedic surgery          |                                 |
| Lyon-II , 3000<br>n=20/20<br>follow-up: 3 weeks                  | Ticlopidine<br>versus<br>placebo | Elective orthopaedic surgery          |                                 |
| Gardecki , 3000<br>n=48/46<br>follow-up: 2 weeks                 | Ticlopidine<br>versus<br>placebo | Elective orthopaedic surgery          |                                 |
| McKenna-II , 1983<br><i>unpublished</i><br>n=27/26<br>follow-up: | Ticlopidine<br>versus<br>placebo | high risk (post CVA) medical patients | Parallel groups<br>double-blind |

More details and results :

- antithrombotics for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q37>
- antithrombotics for thrombosis prevention in medical patients at <http://www.trialresultscenter.org/go-Q87>
- antithrombotics for thrombosis prevention in general surgery at <http://www.trialresultscenter.org/go-Q92>
- antiplatelets drug for thrombosis prevention in orthopedic surgery at <http://www.trialresultscenter.org/go-Q186>
- antiplatelets drug for thrombosis prevention in general surgery at <http://www.trialresultscenter.org/go-Q461>
- antiplatelets drug for thrombosis prevention in all type of patients at <http://www.trialresultscenter.org/go-Q462>
- antiplatelets drug for thrombosis prevention in medical patients at <http://www.trialresultscenter.org/go-Q463>
- antiplatelets drug for thrombosis prevention in elective orthopedic surgery at <http://www.trialresultscenter.org/go-Q464>

## References

### **Lasierra, 1982:**

Lasierra J, Arevalo A, Vilades E, Hebrero J, Espinosa H, Yanguela J, et al. Effect of ticlopidin on the risk of thromboembolic disease in the pistoperation. Haemostasis 1982;12:104.

### **Walker, 1974:**

unpublished

Walker MG. Assessment of effect of ticlopidine on intcidence of deep vein thrombosiu in patients undergoing major surgery Guildford: Sanofi Winthrop, 1983. (Sanofi intemal report 001.6.245.)

### **McKenna-II, 1983:**

McKenna R, Galante J, Molony B, Kamm B. Failure of ticlopidine hydrochloride to prevent DVT in orthopedic patients Blood 1983;62(suppl I):304A

### **Lyon-II, 3000:**

### **Gardecki, 3000:**

### **McKenna-II , 1983:**

unpublished

Graham A. A trial of tcopdne hydrochloride for the prevnon of deep vein thrombosis in high risk (post CVA) medical patients Guildford: Sanofi Winthrop, 1983. (Sanofi intemal report 1983. 001.6.188.)

## 6 diabetes type 2

| Trial  | Treatments                                   | Patients   | Trials design and methods       |
|--|--|--|---------------------------------|
| <b>ticlopidine vs placebo</b>  |  |  |                                 |
| <b>Birmingham-A , 1979</b><br><i>unpublished</i><br>n=20/8<br>follow-up: 2 months      | -  | -  | Parallel groups                 |
| <b>London diabetes , 1983</b><br><i>unpublished</i><br>n=38/40<br>follow-up: 12 months | -  | -  | Parallel groups                 |
| <b>TIMAD , 1984</b><br>n=220/215<br>follow-up: 32m                                     | -  | -  | Parallel groups                 |
| <b>BTRS , 1992</b><br>n=49/51<br>follow-up: 48 months                                  | ticlopidine 500mg/d<br>versus<br>placebo     | insulin-treated diabetics with background<br>retinopathy | Parallel groups<br>double blind |
| <b>Nyberg , 1984</b><br>n=12/11<br>follow-up: 12 months                                | ticlopidine 500mg daily<br>versus<br>placebo | insulin dependent diabetes complicated<br>by nephropathy | Parallel groups<br>double blind |

∞ More details and results :

- antiplatelets drug for diabetes type 2 in patients without cardiovascular disease at <http://www.trialresultscenter.org/go-Q221>
- antiplatelets drug for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q362>

## References

### **Birmingham-A, 1979:**

unpublished

Pollock A, Wright AD Guildford: Sanofi Winthrop, 1979:(Sanofi internal report 105602-0010)

### **London diabetes, 1983:**

unpublished

Oakley NW, Dormandy JA, Flute PT. Guildford: Sanofi Winthrop, 1983:(Internal report 105602-0019.)

### **TIMAD, 1984:**

Mirouze J Agents Actions 1984;15(suppl):230-58

### **BTRS, 1992:**

Ophthalmologica 1992;204:4-12 [[1579337](#)]

### **Nyberg, 1984:**

Nyberg G, Larsson O, Westberg NG, Aurell M, Jagenburg R, Blohm G Clin Nephrol 1984;21:184-7 [[6705280](#)]



## 7 stent

| Trial  | Treatments  | Patients | Trials design and methods |
|--|---|----------|---------------------------|
| <b>ticlopidine + aspirin vs aspirin</b>                      |   |          |                           |
| STARS (vs aspirin) , 1998<br>n=546/557<br>follow-up:         | Ticlopidine 250 mg BID 4 wks Aspirin<br>325 mg qDDage/pj<br>versus<br>Aspirin 325 mg qD                                   | -        |                           |
| Hall , 1996<br>n=13/103                                      | Ticlopidine 250 mg BID 1 mo Aspirin 325<br>mg qD 5 days<br>versus<br>Aspirin 325 mg qD                                    | -        |                           |
| <b>ticlopidine + aspirin vs coumadin + aspirin</b>           |   |          |                           |
| STARS (vs coumadin+asp)<br>, 1998<br>n=546/550<br>follow-up: | Ticlopidine 250 mg BID x4 wks Aspirin<br>325 mg qD<br>versus<br>Coumadin INR 2.5 x4 wks Aspirin 325<br>mg qDBID           | -        |                           |
| FANTASTIC , 1998<br>n=243/230                                | Ticlopidine 250 mg BID 6 wks Aspirin<br>100325 mg qD<br>versus<br>Coumadin INR 2.53.0 6 wks Aspirin<br>100325 mg qD/pj    | -        |                           |
| ISAR , 1996<br>n=257/260<br>follow-up:                       | Ticlopidine 250 mg BID 4 wks Aspirin<br>100 mg BIDage/pj<br>versus<br>Coumadin INR 3.54.5 4 wks Aspirin 100<br>mg BID     | -        |                           |
| MATTIS , 1998<br>n=177/173                                   | Ticlopidine 250 mg BID 30 days Aspirin<br>250 mg qD<br>versus<br>Coumadin INR 2.53.0 x30 days Aspirin<br>250 mg qDg qD/pj | -        |                           |
| Foussas , 2000<br>n=203/201                                  | Ticlopidine 500mg qD 1 mo Aspirin 325<br>mg qD<br>versus<br>Coumadin INR 2.3 x4 wks Aspirin 325 mg<br>qDg BID             | -        |                           |

More details and results :

- antithrombotics for stent in all type of patients at <http://www.trialresultscenter.org/go-Q151>

## References

### STARS (vs aspirin), 1998:

Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-71 [9834303]

### Hall, 1996:

Hall P, Nakamura S, Maiello L, Itoh A, Blengino S, Martini G, Ferraro M, Colombo A A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996;93:215-22 [8548891]

### STARS (vs coumadin+asp), 1998:

Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-71 [9834303]

### FANTASTIC, 1998:

Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, Vrolix M, Missault L, Chierchia S, Casaccia M, Niccoli L, Oto A, White C, Webb-Peploe M, Van Belle E, McFadden EP Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998;98:1597-603 [9778323]

### ISAR, 1996:

Schmig A, Neumann FJ, Kastrati A, Schhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9 [8598866]

### MATTIS, 1998:

Urban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuelsson H, Fontanelli A, Pieper M, Wesseling T, Sagnard L Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998;98:2126-32 [9815866]

### Foussas, 2000:

Foussas S, Alexopoulos D, Stefanadis C, Olympios C, Voudris V, Hatzimiltiadis S, Sionis D, Vavouranakis E, Vrahatis A, Fakiolas C, Pissimisis E, Stefanidis A, Zairis M, Pavlides G, Vitakis S, Louridas G, Cokkinos D, Toutouzas P Antiplatelet is superior to anticoagulant treatment after coronary stenting: fewer coronary and other events within 30 days after stenting. Angiology 2000;51:289-94 [10778998]

## 8 coronary artery disease

| Trial                  | Treatments | Patients | Trials design and methods |
|------------------------|------------|----------|---------------------------|
| ticlopidine vs placebo |            |          |                           |

continued...

| Trial                                       | Treatments                                    | Patients  | Trials design and methods       |
|---|---|---|---------------------------------|
| Berglund , 1985<br>n=21/17<br>follow-up: 2m | ticlopidine 500 mg daily<br>versus<br>placebo | middle-aged men with stable<br>incapacitating angina pectoris | parallel groups<br>double blind |

More details and results :

- death and events prevention for coronary artery disease in all type of patients at <http://www.trialresultscenter.org/go-Q450>

## References

### Berglund, 1985:

Berglund U, von Schenck H, Wallentin L Effects of ticlopidine of platelet function in men with stable angina pectoris. Thromb Haemost 1985;54:808-12 [3911481]

## 9 CABG surgery

| Trial  | Treatments  | Patients  | Trials design and methods |
|--|---|---|---------------------------|
| <b>ticlopidine vs control</b>                  |   |   |                           |
| Zurich , 1982<br>n=50/50<br>follow-up: 3m      | -   | -   |                           |
| Knudsen-B , 1983<br>n=9/10<br>follow-up: 6m    | -   | -   |                           |
| Romeo , 1983<br>n=20/20<br>follow-up: 3m (12m) | -   | -   |                           |
| Kohn , 1990<br>n=21/24<br>follow-up: 14d       | -   | -   |                           |
| <b>ticlopidine vs placebo</b>                  |   |   |                           |
| Lige-I , 1984<br>n=75/75<br>follow-up: 3m      | ticlopidine 250 mg twice daily<br>versus<br>placebo | patients undergoing aortocoronary bypass<br>graft procedures  | double blind              |
| Lige-II , 1987<br>n=88/87<br>follow-up: 12m    | ticlopidine 250 mg twice daily<br>versus<br>placebo | patients undergoing venous coronary<br>artery bypass grafting | double blind              |

More details and results :

- antiplatelets drug for CABG surgery in all type of patients at <http://www.trialresultscenter.org/go-Q225>

## References

### Zurich, 1982:

Rothlin ME, Pflger K, Speiser K, Geroulanos SJ, Goebel N, Turina M, et al4 Clinical experience with anti-platelet drugs in aorta-coronary bypass surgery Coronary Artery Disease Today 1982;557:413-9

### Knudsen-B, 1983:

Mortensen SA, Knudsen JB, Hjelms E, Efsen F. Pre- and post-operative platelet inhibition with ticlopidine in connexion with coronary artery bypass surgery (CABG).r=n Eur Heart J 1983;4 (suppl 3):Abstract 001 F.

### Romeo, 1983:

Romeo F, Ruvolo G, Martuscelli E, Comito M, Cardona N, Colistra C, et al.gery Ticlopidine in the prevention of the block of aorto-coronary by-passP Proceedings of satellite symposium of 83rd Congress of Italian society of Internal Medicine. Rome: 1982:155-60

### Kohn, 1990:

Kohn RN. Study of the safety of perioperative administration of ticlopidine hydrochloride in coronary artery bypass surgery.eur=n Guildford: Sanofi Winthrop, 1990 (Sanofi internal report 001.6.186)

### Lige-I, 1984:

Chevign M, David JL, Rigo P, Limet R Effect of ticlopidine on saphenous vein bypass patency rates: a double-blind study. Ann Thorac Surg 1984;37:371-8 [6608929]

### Lige-II, 1987:

Limet R, David JL, Magotteaux P, Larock MP, Rigo P Prevention of aorta-coronary bypass graft occlusion. Beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. J Thorac Cardiovasc Surg 1987;94:773-83 [3312825]

## 10 peripheral vascular diseases

| Trial   | Treatments  | Patients                | Trials design and methods         |
|---|---|-------------------------|-----------------------------------|
| <b>ticlopidine vs contrle</b>                       |   |                         |                                   |
| Bequemins , 1997<br>n=122/121<br>follow-up: 24 mois | Ticlopidine (Ticlid, sanofi) 250 mg*2 /j<br>versus<br>placebo | Patients au stade II IV | Parallel groups<br>Double aveugle |
| <b>ticlopidine vs placebo</b>                       |   |                         |                                   |
| Ellis , 1986<br>n=100/103<br>follow-up: 6 months    | Ticlopidine 500 mg/j<br>versus<br>Placebo                     | AOMI stade II           | Parallel groups<br>double blind   |

continued...

| <b>Trial</b>   | <b>Treatments</b>   | <b>Patients</b>   | <b>Trials design and methods</b> |
|--|---|---|----------------------------------|
| <b>Hurlow , 1980</b><br>n=30/30<br>follow-up:                | Ticlopidine : 100 -500 mg / jour pendant 2 mois.<br>versus<br>Placebo | Donnes non disponibles  | Parallel groups<br>double blind  |
| <b>Krause , 1980</b><br>n=19/19<br>follow-up:                | Ticlopidine : 500 mg pendant 4 mois<br>versus<br>Placebo              | Donnes non disponibles  | Parallel groups<br>double blind  |
| <b>Katsumara , 1982</b><br>n=93/100<br>follow-up: 6 semaines | Ticlopidine 500 mg/j<br>versus<br>Placebo                             | patients with ischemic ulcers due to chronic arterial occlusion   | Parallel groups<br>double blind  |
| <b>Aukland , 1982</b><br>n=33/32<br>follow-up: 1 y           | Ticlopidine 500 mg/j<br>versus<br>Placebo                             | men with atherosclerotic intermittent claudication and haemorheological abnormalities                     | Parallel groups<br>double blind  |
| <b>Stiegler , 1984</b><br>n=57/57<br>follow-up:              | Ticlopidine 500 mg/j<br>versus<br>Placebo                             | AOMI stade II   | Parallel groups<br>double blind  |
| <b>Cloarec , 1986</b><br>n=66/66<br>follow-up: 1 y           | Ticlopidine 500 mg/j<br>versus<br>Placebo                             | AOMI stade non precis   | Parallel groups<br>double blind  |
| <b>Arcan , 1988</b><br>n=83/86<br>follow-up: 6 months        | Ticlopidine 500 mg/j<br>versus<br>Placebo                             | patients with chronic intermittent claudication due to obstructive peripheral vascular disease (stade II) | Parallel groups<br>double blind  |
| <b>Balsano , 1989</b><br>n=76/75<br>follow-up: 21 months     | Ticlopidine 500 mg/j<br>versus<br>Placebo                             | patients with intermittent claudication (stade II)  | Parallel groups<br>double blind  |
| <b>STIMS , 1990</b><br>n=346/341<br>follow-up: 5.6 y         | Ticlopidine 500 mg/j<br>versus<br>Placebo                             | patients with intermittent claudication (stade II)  | Parallel groups<br>double blind  |
| <b>EMATAP , 1993</b><br>n=304/311<br>follow-up:              | Ticlopidine 500 mg/j<br>versus<br>Placebo                             | AOMI stade non precis   | Parallel groups<br>double blind  |

More details and results :

- antiplatelets drug for peripheral vascular diseases in all type of patient at <http://www.trialresultscenter.org/go-Q278>
- antithrombotics for peripheral vascular diseases in after revascularisation at <http://www.trialresultscenter.org/go-Q661>

## References

**Becquemin, 1997:**

Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine apres Pontage Femoro-Poplite and the Association Universitaire de Recherche en Chirurgie. Becquemin JP N Engl J Med 1997 Dec 11;337:1726-31 [[9392698](#)]

**Ellis, 1986:**

DJ Ellis, BR Kamm. Treatment of intermittent claudication with Ticlopidine. Institute of Clinical Medicine, Syntex Research. Palo Alto.CA 94304, USA. Modifier — Effacer — pdf

**Hurlow, 1980:**

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration BMJ 2002 Jan 12;324:71-86 [[11786451](#)]

**Krause, 1980:**

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration BMJ 2002 Jan 12;324:71-86 [[11786451](#)]

**Katsumara, 1982:**

Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases, a double-blind study versus placebo. Katsumura T, Mishima Y, Kamiya K, Sakaguchi S, Tanabe T, Sakuma A Angiology 1982 Jun;33:357-67 [[7046521](#)]

**Aukland, 1982:**

Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication. Aukland A, Hurlow RA, George AJ, Stuart J J Clin Pathol 1982 Jul;35:740-3 [[7047575](#)]

**Stiegler, 1984:**

H Stiegler, H Hess, A Mietaschk, H-J, Trampisch and Ingrisich. DMW 1984, 109:1240-1243.

**Cloarec, 1986:**

Cloarec M et al Double-blind clinical trial of ticlopidine versus placebo in peripheral atherosclerotic disease of the legs Thrombosis Research 1986 suppl VI abstr 316

**Arcan, 1988:**

Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Arcan JC, Blanchard J, Boissel JP, Destors JM, Panak E Angiology 1988 Sep;39:802-11 [[3048155](#)]

**Balsano, 1989:**

Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. Balsano F, Coccheri S, Libretti A, Nenci GG, Catalano M, Fortunato G, Grasselli S, Violi F, Hellemans H, Vanhove P J Lab Clin Med 1989 Jul;114:84-91 [[2661700](#)]

**STIMS, 1990:**

Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. Janzon L, Bergqvist D, Boberg J, Boberg M, Eriksson I, Lindgarde F, Persson G, Almgren B, Fagher B, Kjellstrom T, et al J Intern Med 1990 May;227:301-8 [[2187948](#)]

**EMATAP, 1993:**

J Blanchard, LO Carrerars, M Kindermans and the EMATAP group. Results of EMATAP: a dooble-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease. Nouv Rev fr Hematol( 1993)35:523-528.

## 11 percutaneous coronary intervention

| Trial  | Treatments  | Patients | Trials design and methods |
|--|---|----------|---------------------------|
| <b>ticlopidine vs placebo</b>                                |   |          |                           |
| TACT , 1990<br>n=177/173<br>follow-up: 6m                    | -   | -        | Parallel groups           |
| White (ticlopidine) , 1991<br>n=NA<br>follow-up: 6m          | ticlopidine 500, aspirin 650 + D225<br>versus<br>placebo  | -        | Parallel groups           |
| <b>ticlopidine + aspirin vs aspirin</b>                      |   |          |                           |
| STARS (vs aspirin) , 1998<br>n=546/557<br>follow-up:         | Ticlopidine 250 mg BID 4 wks Aspirin<br>325 mg qDDage/pj<br>versus<br>Aspirin 325 mg qD                                   | -        |                           |
| Hall , 1996<br>n=13/103                                      | Ticlopidine 250 mg BID 1 mo Aspirin 325<br>mg qD 5 days<br>versus<br>Aspirin 325 mg qD                                    | -        |                           |
| <b>ticlopidine + aspirin vs coumadin + aspirin</b>           |   |          |                           |
| STARS (vs coumadin+asp)<br>, 1998<br>n=546/550<br>follow-up: | Ticlopidine 250 mg BID x4 wks Aspirin<br>325 mg qD<br>versus<br>Coumadin INR 22.5 x4 wks Aspirin 325<br>mg qDBID          | -        |                           |
| FANTASTIC , 1998<br>n=243/230                                | Ticlopidine 250 mg BID 6 wks Aspirin<br>100325 mg qD<br>versus<br>Coumadin INR 2.53.0 6 wks Aspirin<br>100325 mg qD/pj    | -        |                           |
| ISAR , 1996<br>n=257/260<br>follow-up:                       | Ticlopidine 250 mg BID 4 wks Aspirin<br>100 mg BIDage/pj<br>versus<br>Coumadin INR 3.54.5 4 wks Aspirin 100<br>mg BID     | -        |                           |
| MATTIS , 1998<br>n=177/173                                   | Ticlopidine 250 mg BID 30 days Aspirin<br>250 mg qD<br>versus<br>Coumadin INR 2.53.0 x30 days Aspirin<br>250 mg qDg qD/pj | -        |                           |

continued...

| Trial                       | Treatments   | Patients | Trials design and methods |
|-----------------------------|--|----------|---------------------------|
| Foussas , 2000<br>n=203/201 | Ticlopidine 500mg qD 1 mo Aspirin 325 mg qD<br>versus<br>Coumadin INR 23 x4 wks Aspirin 325 mg qDg BID | -        |                           |

More details and results :

- antithrombotics for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q63>
- antithrombotics for percutaneous coronary intervention in PCI with stent placement at <http://www.trialresultscenter.org/go-Q152>
- antiplatelets drug for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q389>

## References

### TACT, 1990:

Bertrand ME, Allain H, LaBlanche JM, on behalf of Investigators of the TACT Study Results of a randomized trial of ticlopidine versus placebo for prevention of acute closure and restenosis after coronary angioplasty (PTCA): the TACT study *Circulation* 1990;82(suppl III):190 (Abstract 0754)

### White (ticlopidine), 1991:

### STARS (vs aspirin), 1998:

Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. *N Engl J Med* 1998;339:1665-71 [9834303]

### Hall, 1996:

Hall P, Nakamura S, Maiello L, Itoh A, Blengino S, Martini G, Ferraro M, Colombo A A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. *Circulation* 1996;93:215-22 [8548891]

### STARS (vs coumadin+asp), 1998:

Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. *N Engl J Med* 1998;339:1665-71 [9834303]

### FANTASTIC, 1998:

Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, Vrolix M, Missault L, Chierchia S, Casaccia M, Niccoli L, Oto A, White C, Webb-Peploe M, Van Belle E, McFadden EP Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. *Circulation* 1998;98:1597-603 [9778323]

### ISAR, 1996:

Schmig A, Neumann FJ, Kastrati A, Schhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. *N Engl J Med* 1996;334:1084-9 [8598866]



**MATTIS, 1998:**

Urban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuelsson H, Fontanelli A, Pieper M, Wesseling T, Sagnard L Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). *Circulation* 1998;98:2126-32 [[9815866](#)]

**Foussas, 2000:**

Foussas S, Alexopoulos D, Stefanadis C, Olympios C, Voudris V, Hatzimiltiadis S, Sionis D, Vavouranakis E, Vrahatis A, Fakiolas C, Pissimisis E, Stefanidis A, Zairis M, Pavlides G, Vitakis S, Louridas G, Cokkinos D, Toutouzas P Antiplatelet is superior to anticoagulant treatment after coronary stenting: fewer coronary and other events within 30 days after stenting. *Angiology* 2000;51:289-94 [[10778998](#)]

Entry terms: Ticlopidine, Ticlopidine Hydrochloride, Ticlodix, Ticlodone, 53-32C, 53 32C, 5332C, Ticlid,